Podcasts about PFS

Oct 30, 2025 – Will gold and silver continue their meteoric rise—or are we on the cusp of a major correction? In this insightful interview, market strategist Kurt Kallaus joins Cris Sheridan to unpack the powerful forces shaping today's markets...

Oct 28, 2025 – Presidents Trump and Xi prepare to meet on October 30 in South Korea during the Asia-Pacific Economic Cooperation (APEC) summit. This high-stakes meeting could reshape global trade dynamics and supply chains amid ongoing...

Oct 28, 2025 – Wondering where the next big market move is? Jonathan Petersen of Variant Perception reveals resilient U.S. and Chinese growth, risk-on signals for equities and commodities, bubble warning signs, and actionable allocation...

Oct 27, 2025 – Looking to keep more of your retirement income? Jim Puplava shares four key tax-minimizing strategies: Roth conversions, muni bonds, LIRPs, and dividend income—plus tips on planning ahead as tax rates may rise with growing...

Brendan Yurik joins the KE Report to discuss Electric Royalties (TSX.V:ELEC - OTC:ELECF) expanding portfolio and path to sustainable cash flow. The company now holds 43 royalties focused on key electrification metals across top-tier jurisdictions. Discussion Highlights First Cash-Flowing Asset: Copper-gold royalty at the Punitaqui Copper Mine (Chile) ramping up - expected to cover annual G&A. Next in Line: Four royalties could begin paying within 12 months. Advancing Projects: Feasibility and PFS updates coming from multiple assets. Diversified Exposure: Balanced across copper, lithium, graphite, manganese, nickel, zinc, tin, and vanadium; no single asset >15% of NAV. Growth Outlook: Targeting one or two near-term, revenue-generating royalties backed by private equity to boost cash flow with minimal dilution. Click here to visit the Electric Royalties website to learn more about the Company   -------------- For more market commentary & interview summaries, subscribe to our Substacks: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

As part of the European Society for Medical Oncology (ESMO) Congress 2025, CancerNetwork® spoke with a variety of experts about key takeaways from different late-breaking abstracts, oral presentations, and other sessions focused on potential advancements across cancer care. Presenting investigators highlighted updated results from clinical trials evaluating novel therapeutic strategies across different cancer populations, including breast cancer and lung cancer.  Phase 3 VIKTORIA-1 Trial Sara A. Hurvitz, MD, FACP, the Smith Family Endowed Chair in Women's Health and senior vice president and director of the Clinical Research Division at the Fred Hutch Cancer Center, and tumor chair in breast oncology for the ONCOLOGY® editorial advisory board, first discussed findings from the phase 3 VIKTORIA-1 trial (NCT05501886). Her presentation highlighted how VIKTORIA-1 was “the first study to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival [PFS] with PAM inhibition” for patients with PIK3CA wild-type advanced breast cancer. Data from the trial showed that gedatolisib plus fulvestrant (Faslodex) and palbociclib (Ibrance) produced a median PFS of 9.3 months (95% CI, 7.2-16.6) vs 2.0 months (95% CI, 1.8-2.3) with fulvestrant alone (HR, 0.24; 95% CI, 0.17-0.35; P

Oct 25, 2025 – Gold and silver are surging, but is this just the beginning? Financial Sense's Jim Puplava and Dave Morgan of The Morgan Report explore the forces behind skyrocketing prices, from tightening global stockpiles to unprecedented...

October 24, 2025 – Explore the escalating global “resource wars” as Jim Puplava and Cris Sheridan break down how the US and China are racing to secure critical minerals for economic and military dominance. Discover why rare earths, gold, and silver are at the heart of today's geopolitical power plays, and how shifts in monetary policy, reindustrialization, and global alliances are reshaping the...

Oct 24, 2025 – Is it time to get defensive? Jim Puplava sits down with John Kosar of Asbury Research for a candid look at what's happening beneath the surface of these record highs. They dive into the influence of big tech, shifting...

Oct 23, 2025 – HydroGraph CEO Kjirstin Breure discusses how scalable, high-purity graphene is powering breakthroughs in batteries, biosensors, and more—reshaping advanced manufacturing and supply chains. For investors, analysts, and industry...

Oct 22, 2025 – Is the S&P 500's relentless advance setting the stage for a generational reversal? In this in-depth conversation, renowned Elliott Wave strategist Avi Gilburt, co-founder of ElliottWaveTrader.net, lays out a rigorously technical case...

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

In this KE Report company update, I speak with Nick Appleyard, President & CEO of TriStar Gold (TSX.V:TSG - OTCQB:TSGZF), for a detailed overview of the company's flagship Castelo de Sonhos Gold Project in Pará State, Brazil. The discussion revisits the May 2025 Pre-Feasibility Study (PFS) and outlines why TriStar's 2.5 million ounces of gold (1.4 million in reserves) represent an undervalued asset. Key Discussion Highlights: Robust Resource & Reserves: The project hosts 2.5Moz total gold, including 1.4Moz of reserves, supported by over 75,000m of drilling. The deposit remains open and continuous, with mineralization starting at surface. Project Economics: The May 2025 PFS outlined an AISC of $1,111/oz and an initial CAPEX of ~US$300M (including 20% contingency). Even at $1,500 gold, the project remains profitable. Favorable Geology: The Esperança South zone anchors the project's economics - hosting a 6km-long, shallowly dipping orebody averaging ~1.3 g/t Au with 98% metallurgical recovery. Permitting & Legal Update: TriStar's key LP environmental permit remains in full standing. A pending court clarification expected in November 2025 should resolve current legal challenges, followed by advancement toward the construction permit by late 2026. Strong Downside Protection: At current valuations (~C$60M market cap), TriStar trades below 0.1x NAV. Click here to visit the TriStar Gold website to learn more about the Company and Project.  Email me any follow up questions for Nick - Fleck@kereport.com.   ----------- For more market commentary & interview summaries, subscribe to our Substacks: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Oct 21, 2025 – If you've ever been curious about the true health benefits of sauna sessions and red light therapy, you're in good company. In this engaging conversation, Jim Puplava welcomes Vic Riffel from Sunlighten for an in-depth discussion...

IAMGOLD is consolidating around the Nelligan Mining Complex with the acquisitions of both Northern Superior Resources and Mines D'Or Orbec. Arizona Sonoran Copper has published its PFS for the Cactus Project. Collective Mining shared an exploration update from Colombia. Vizsla Copper published new drill results from Poplar. Prospector Metals shared final drill results from this recent campaign. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

In this KE Report Company Update, we welcome back Caleb Stroup, President & CEO of Headwater Gold (CSE:HWG - OTCQB:HWAUF), for a deep dive into a flurry of recent developments across the company's Nevada and Idaho exploration portfolio.   Key Highlights: Spring Peak – Newmont Stage 2 Earn-In: Newmont to spend US$40M over 3 years to earn up to 65%. The project is now part of the U.S. FAST-41 program, expediting permitting for a 266-site drill program. Loadstar – Drilling Underway: Maiden 3,500m (10–15 hole) drill program testing the Zodiac-Sinister Ridge target for high-grade epithermal veins, modeled after the Spring Peak discovery. OceanaGold Partnership: Signed definitive deal covering TJ, Jake Creek & Hot Creek projects. OceanaGold can earn up to 75% by spending US$65M and completing PFS studies. Drilling underway at TJ. Crane Creek (Idaho): 100%-owned; newly permitted and drill-ready. Evaluating self-funding vs. partner option. Strong Backing: Recent C$1M raise led by Rick Rule, Jeff Phillips, and Centerra Gold; year-end cash estimated at C$2.5–3M. Please email your questions for Caleb to us at Fleck@kereport.com and Shad@kereport.com.  Click here to visit the Headwater Gold website to read over the recent news.   ----------- For more market commentary & interview summaries, subscribe to our Substacks: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/   Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Oct 17, 2025 – With equity markets brushing new highs but warning signs flashing in credit spreads, how should discerning investors position themselves? Amid renewed US-China trade tensions and volatile headlines, Chris Puplava highlights...

Oct 17, 2025 – Is the world ready for China's long game? In The Long Game: China's Grand Strategy to Displace American Order, Rush Doshi reveals how China has quietly and methodically plotted to supplant U.S. global leadership once...

Oct 17, 2025 – What happens when America's $37 trillion debt collides with China's stranglehold on critical materials? In this urgent conversation, Jim Puplava interviews energy expert Robert Bryce about two existential threats facing the United States...

Oct 15, 2025 – Satyajit Das reveals the reasons behind gold's parabolic rise: ongoing trade friction, US debt concerns, discussions over capital controls, and the BRICS challenge. As policymakers grapple with inconsistent agendas and the specter...

Oct 14, 2025 – AI circular financing raises concerns as firms invest trillions in infrastructure amid lagging user adoption and free Chinese models. With tech CapEx at 4.5% of GDP, risks loom if revenue growth and monetization don't materialize soon...

Newly enacted regulations may have an impact on the how your charitable tax deductions will be treated by the IRS. Today, John Walker, Regional Vice President, Mercer Advisors, is joined by CERTIFIED FINANCIAL PLANNER® professional Jason O'Meara, Wealth Advisor and Sr. Director, Mercer Advisors along, with Mercer Advisors colleague Bryan Strike, MS, MTx, CFA, CFP®, CPA, PFS, CIPM, RICP®, CPWA®, CAS, Director of Financial Planning. They discuss how you may be impacted by the changes. Listening Time: 28 minutes Mercer-Cordasco Disclosure Information Visit Our Website Join Our Email List Additional Mercer Advisors Disclosure Cordasco Financial Network is a tradename. All services provided by Cordasco Financial Network investment professionals are provided in their individual capacities as investment adviser representatives of Mercer Global Advisors Inc. (“Mercer Advisors”), an SEC-registered investment adviser principally located in Denver, Colorado, with various branch offices throughout the United States doing business under different tradenames, including Cordasco Financial Network. Mercer Advisors is not a law firm and does not provide legal advice to clients. All estate planning document preparation and other legal advice are provided through Advanced Services Law Group, Inc.

Oct 13, 2025 – Nearing 65? Jim Puplava and Medicare expert Brian McArthur clarify enrollment periods, plan options, and strategies—covering Original Medicare, supplements, Advantage plans, international coverage, and penalties...

Oct 10, 2025 – What if the U.S. stock market's record-breaking concentration is secretly propping up the entire Treasury market? Jim Puplava sits down with Doomberg to explore this precarious link and the high-stakes economic war with China...

Oct 10, 2025 – Are resource stocks the next big wave investors can't afford to miss? In this lively interview, Jim Puplava and Larry McDonald dissect the explosive rise of natural resources—gold, silver, copper, and uranium—outperforming...

Oct 10, 2025 – Is the market rally fading? Mish Schneider joins Jim Puplava to decode warning signs in retail, banks, and transports using her "Economic Modern Family." Dive into risks, AI, and gold's surge. Listen for key insights!

Oct 9, 2025 – Gold and silver hit record highs—is this the end or just a pause before another surge? CPM Group's Jeff Christian joins Cris Sheridan to unpack what's driving the rally and whether more gains could be ahead for precious metals investors...

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today.• Draganfly (CSE: DPRO) — Defense Push with Global OrdnanceDraganfly signed a strategic partnership with DLA prime contractor Global Ordnance to fast-track U.S. defense adoption of its Commander 3XL and Flex FPV drones. The plan: leverage government contracting channels, localize manufacturing, and harden supply chains for NDAA-compliant, mission-ready systems.• West Red Lake Gold (TSXV: WRLG) — Big Hits at Madsen's Lower AustinWRLG reported some of its strongest underground intercepts yet: 139.45 g/t Au over 7.8 m, 74.70 g/t over 8.7 m, and 18.31 g/t over 7.5 m. Results suggest ~600 m of high-grade continuity tying into South Austin—supportive of its 2025 restart plan framed by a PFS with reserves and strong projected cash flow.• Scottie Resources (TSXV: SCOT) — High Grade + Bulk Sample MilestoneAt the Blueberry Contact Zone, Scottie hit 8.37 g/t Au over 8.45 m and 122 g/t over 1.2 m. Its largest program to date (5 rigs, >25,000 m) targets resource upgrades ahead of a Q4 PEA evaluating a capital-light DSO/toll-processing route. The 10,000-tonne bulk sample is mined, crushed, and shipped—assays pending.• Clean Air Metals (TSXV: AIR) — Capital-Light PEA at Thunder Bay NorthNew PEA outlines an 11-year, 2,500 tpd ramp-access mine using toll milling: pre-tax NPV8 C$219.4M, 39% IRR, C$89.5M initial capex, 2.5-year payback (spot case lifts to C$316M NPV and 52% IRR). Updated resources: 14.9 Mt indicated at 2.66 g/t 2PGE, 0.40% Cu, 0.24% Ni; 2.49 Mt inferred at 1.62 g/t 2PGE, 0.31% Cu, 0.19% Ni.• Benton Resources (TSXV: BEX) — Portfolio Leverage to AIR PEABenton owns 24.6M shares (9.8%) of Clean Air Metals and a 0.5% NSR on parts of Thunder Bay North. The AIR PEA's strong returns and low capex provide two potential value streams for Benton—equity upside and future royalty exposure—while Benton advances its own high-grade Great Burnt Cu-Au project.For more breaking small-cap news and real-time updates, follow AGORACOM across all channels—and don't miss our podcast for deep dives and interviews. 

Oct 7, 2025 – What powers our digital world? Journalist Guillaume Pitron reveals the hidden costs—rare metals, energy-guzzling data centers, and global supply chains—behind emails, AI, and streaming in The Dark Cloud. Listen and see tech differently...

Karen Berisford, Chartered Financial Planner and Fellow of the PFS, left a prestigious investment role at JP Morgan to build a client-first advice practice with St. James's Place. She prioritised trust, time control, and service over scale-at-all-costs.In this episode of the Financial Planner Life podcast, Karen shares how she grew to £150M AUM without relying on social media or paid marketing. Instead, she focused on referrals and long-term, values-led growth.You'll learn:How to transition from investments to adviceThe fear and reward of becoming client-facingTurning one ex-colleague's “yes” into a thriving networkWhy trust, consistency, and integrity beat any sales pitchThe realities of flexible working when you run your own practiceHow the Women Returners Network helped her hire two standout advisersThe compounding effect of delegation, leadership, and supportThe key benefits of the SJP partnership modelWhy building optionality starts long before a saleIf you're serious about building a meaningful career in financial planning, this is your blueprint.

Oct 6, 2025 – Are record-high markets making your IRA balloon—and your tax worries grow? Jim Puplava and Crystal Colbert break down how market surges impact IRAs, explore Roth conversions, and share smart tax-saving strategies for retirees...

In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025. Key topics included: • Overview of the IMforte study design and patient population • The role of lurbinectedin and atezolizumab as maintenance therapy • Significant improvements in progression-free survival (PFS) and overall survival (OS) • Management of side effects and the importance of prophylactic growth factors • Patient selection criteria for this new standard of care With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers! #IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC

Oct 3, 2025 – Are the “Mag 7” tech giants losing ground to the “Shiny 7” metals and mining stocks? Financial Sense Newshour's Jim Puplava and Jim Welsh at Macro Tides examine Wall Street's record highs, the broadening bull market...

Oct 3, 2025 – Jordan Roy-Byrne breaks down the historic breakout from a 13-year cup and handle pattern, the crucial signal of gold outperforming the traditional 60/40 portfolio, and the impact of central bank buying and de-dollarization...

Oct 2, 2025 – Laser weapons are moving from science fiction to the front lines, and they could soon be a pillar of national defense. In this eye-opening interview, Applied Energetics CEO Chris Donaghey explains how directed energy weapons are...

October 1, 2025 – Did you know that 99.9% of US businesses are small businesses? In this must-listen interview, Cris Sheridan sits down with Dan Varroney, author of Rethinking Economic Growth , to reveal why small businesses are the true engine of America's economy and how policy needs to change to reflect this reality. They explore how Main Street entrepreneurs drive innovation, face daunting...

Sep 29, 2025 – Retirement is changing, and the old rules may no longer apply. In this timely interview, Jim Puplava of Financial Sense Wealth Management explains the challenges facing today's retirees, from rising inflation and soaring...

Drs. Fahkri and Seshadri discuss recent studies on novel fixed-duration combinations and MRD-guided regimens for CLL. The Sequoia RMD study showed high efficacy with zanubrutinib and venetoclax, achieving a 99% response rate. Similarly, a phase 1 study with sornotoclax and zanubrutinib showed a 96% response rate. The UK FLAIR study demonstrated superior PFS and overall survival with ibrutinib plus venetoclax. The CLL18 trial evaluates MRD-guided vs. fixed-duration treatments with venetoclax and obinutuzumab or pirtobrutinib. Future CLL therapies may increasingly rely on MRD-guided approaches.

Sep 26, 2025 – If China can build 11 nuclear plants in the time it takes the U.S. to finish one, what does that mean for the future balance of power? Jim Puplava and Cris Sheridan discuss Dan Wang's new book Breakneck: China's Quest...

Sep 27, 2025 – Gold at record highs, silver edging toward $50, and precious metal mining companies—"the Shiny 7" as we call them—are making major moves. In today's Smart Macro segment of the Financial Sense Newshour, Chris Puplava...

Sep 26, 2025 – Financial Sense Newshour's Jim Puplava sits down with Dave Keller, President of Sierra Alpha Research, to get an update on his technical outlook for the market, looking at a variety of market metrics, sectors, and companies that...

Sep 26, 2025 – Curious about the future of uranium and nuclear energy markets? Uranium and nuclear analyst Mart Wolbert discusses the recent move by the US to establish a strategic uranium reserve to shift away from Russian dependency...

Sep 25, 2025 – Industrial policy experts Marc Fasteau and Ian Fletcher discuss the big investments the US is making into a variety of industries and companies as part of their “three pillars of US Industrial Policy," which includes currency adjustments...

We connect with Mike Konnert of Vizsla Silver to discuss the latest financing package from Macquarie Bank for a senior secured project finance facility of up to US$220 million to fund the construction and development of the high-grade underground Panuco silver-gold project in Sinaloa, Mexico. We discuss the timing of this as the company continues its test mining work at site. Mike also shares insights into the work happening for the upcoming PFS later this year.

Sep 19, 2025 – Did you know your dentist could be the key to solving your chronic fatigue? In this revealing interview, Jim Puplava sits down with dental sleep expert Dr. Erela Rappaport to unmask the hidden sleep thief: obstructive sleep apnea...

Sep 20, 2025 – Danielle DiMartino Booth joins Financial Sense's Jim Puplava to unpack the Federal Reserve's recent rate cut, revealing why Fed independence is under pressure and how flawed economic data masks true risks...

Sep 19, 2025 – Markets are hitting record highs—and the rally is broadening beyond tech. Join John Roque at 22V Research and Jim Puplava as they unpack what's driving this shift and where the real opportunities lie. From the ongoing bull market...

Sep 18, 2025 – In a world where blockchain headlines seem quieter than past frenzies, seismic shifts are still reshaping finance behind the scenes. Phil George of EarnOS and FS Insider's Cris Sheridan discuss how stablecoins and tokenization are...

Sep 19, 2025 – What if the future of global power hinged on an unprecedented economic and technological battle? Join Financial Sense Wealth Management President Jim Puplava as he unravels the escalating tensions between...

Sep 16, 2025 – Learn why a non-recessionary growth slowdown might fuel an ongoing bullish surge in stocks, gold, and crypto. Senior Analyst Mike Singleton of Invictus Research speaks with FS Insider today about emerging tariff-induced...